Protagonist Therapeutics (PTGX) revenue

Revenue · fiscal 2025
$46.02M

Protagonist Therapeutics (PTGX) reported revenue of $46.02M in fiscal 2025 (the year ended December 31, 2025). That is 89.4% lower than the $434.43M of fiscal 2024. Figures as of 18 Nov 2026, 11:38 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$46.02M
Change on fiscal 2024
−89.4%
Growth, 5 years
+10.0% a year
Highest on record
$434.43Mfiscal 2024
Lowest on record
$231.00Kfiscal 2019
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Protagonist Therapeutics revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 10.0% a year. Across the 9 fiscal years on record (2017–2025), the highest was $434.43M in fiscal 2024 and the lowest $231.00K in fiscal 2019.

History · 9 fiscal years

Revenue by fiscal year

Protagonist Therapeutics revenue, year by year

Protagonist Therapeutics (PTGX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$46.02M 89.4% down
2024$434.43M 624.1% up
2023$60.00M 125.7% up
2022$26.58M 2.8% down
2021$27.36M 4.4% down
2020$28.63M 12,293.1% up
2019$231.00K 99.3% down
2018$30.93M 54.1% up
2017$20.06M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Protagonist Therapeutics and comparable companies
CompanyRevenueFiscal year
Praxis Precision Medicines PRAX$8.55M2024
Twist Bioscience TWST$459.43M2026
Protagonist Therapeutics PTGX$46.02M2025
Krystal Biotech KRYS$389.13M2025
10x Genomics TXG$642.82M2025
HealthEquity HQY$1.31B2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics revenue: questions and answers

What is Protagonist Therapeutics's revenue?

Protagonist Therapeutics (PTGX) reported revenue of $46.02M in fiscal 2025 (the year ended December 31, 2025). That is 89.4% lower than the $434.43M of fiscal 2024.

What is the growth rate of Protagonist Therapeutics's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 10.0% a year.

What are the highest and lowest revenue figures on record for Protagonist Therapeutics?

Across the 9 fiscal years on record (2017–2025), the highest was $434.43M in fiscal 2024 and the lowest $231.00K in fiscal 2019.

How is Protagonist Therapeutics's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Protagonist Therapeutics it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/PTGX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.